Background: Fibrous cap thickness (FCT), best measured by intravascular optical coherence tomography (OCT), is the most important determinant of plaque rupture in the coronary arteries. Statin treatment increases FCT and thus reduces the likelihood of acute coronary events. However, substantial statin-related FCT increase occurs in only a subset of patients. Currently, there are no methods to predict which patients will benefit. We use transcriptomic data from a clinical trial of rosuvastatin to predict if a patient's FCT will increase in response to statin therapy. Methods: FCT was measured using OCT in 69 patients at (1) baseline and (2) after 8-10 weeks of 40 mg rosuvastatin. Peripheral blood mononuclear cells were assayed via microarray. We constructed machine learning models with baseline gene expression data to predict change in FCT. Finally, we ascertained the biological functions of the most predictive transcriptomic markers. Findings: Machine learning models were able to predict FCT responders using baseline gene expression with high fidelity (Classification AUC = 0.969 and 0.972). The first model (elastic net) using 73 genes had an accuracy of 92.8%, sensitivity of 94.1%, and specificity of 91.4%. The second model (KTSP) using 18 genes has an accuracy of 95.7%, sensitivity of 94.3%, and specificity of 97.1%. We found 58 enriched gene ontology terms, including many involved with immune cell function and cholesterol biometabolism. Interpretation: In this pilot study, transcriptomic models could predict if FCT increased following 8-10 weeks of rosuvastatin. These findings may have significance for therapy selection and could supplement invasive imaging modalities.
Introduction
Acute coronary events most commonly result from atherosclerotic plaque rupture with luminal thrombosis and vessel occlusion. The plaques vulnerable to rupture demonstrate several distinct histomorphological signatures: Fibrous cap thickness (FCT) is the most important determinant of plaque vulnerability, followed by measures of the extent of plaque inflammation and necrotic core size [1, 2] . FCT is best assessed in vivo by optical coherence tomography (OCT) [3] [4] [5] . However, since OCT is an invasive intravascular imaging test, it is not routinely performed. FCT is known to increase in response to statin (HMG-CoA reductase inhibitor) therapy. This increase in FCT is indicative of plaque stabilization. However, observable increases in FCT occur in only a subset of patients following statin therapy, and it would be important to identify these subjects without an invasive imaging modality [6] .
Plaque morphology and composition cannot generally be identified by traditional coronary artery angiography, and numerous imaging modalities, such as intravascular ultrasound (IVUS) [7] , OCT [8] , and near infrared spectroscopy (NIRS) have been employed in clinical practice [9, 10] . Of all the imaging strategies, only OCT imaging is capable of measuring FCT. Noninvasive approaches such as computed tomography angiography [11] are able to identify the extent of necrotic core and expansive remodeling of the lesion sites, and magnetic resonance imaging is able to identify lipid-rich plaques [12] . However, the resolution of the non-invasive imaging modalities is not sufficient for the assessment of FCT. It is therefore important to develop biomarker surrogates of FCT that could distinguish patients who would or would not benefit from statin therapy.
Lipid lowering agents, most prominently statins, increase the FCT of thin-cap fibroatheromas [13] [14] [15] . Statins primarily inhibit the ratelimiting enzyme in cholesterol biosynthesis, HMG-CoA reductase, and also demonstrate pleiotropic effects [6, 16] . The degree of FCT thickening (and therefore protection) caused by statins is positively correlated with the statin dose [17] . Unfortunately, not all patients respond equivalently to statin therapy, and the poor responders experience greater atheroma progression and higher rates of adverse cardiovascular outcomes [18, 19] .
Using OCT imaging, we also observed that only a subset of patients increased the FCT with statin therapy [6] . Usually the statin response is measured by changes in serum lipid levels following the initiation of statin therapy. However, even though there is likely some correlation, serum lipid levels do not directly predict the change in plaque FCT [20] . It is therefore important to non-invasively distinguish responders from non-responders [21] , so that non-responders may seek other therapeutic options. We present a predictive model for FCT response to statin therapy utilizing imaging, clinical data, and gene expression (transcriptomics) from the previously described patients included in the Yellow II clinical trial [6] .
Materials and methods

Ethics statement
Written informed consent was obtained from all patients. This study was approved by the Institutional Review Board of the Icahn School of Medicine at Mount Sinai.
Study design and procedure
We analyzed patient data from the Yellow II clinical trial which has been previously described [6] . Briefly, 85 patients with stable multivessel coronary artery disease underwent percutaneous coronary intervention (PCI) for an obstructive lesion. Lesions had greater than or equal to 70% stenosis as measured via angiographic visual assessment and fractional flow reserve. In the same procedure, a second "non-culprit" lesion was imaged with OCT imaging, and peripheral blood mononuclear cell (PBMC) gene expression was characterized by microarray. Trial patients were then assigned to 40 mg daily rosuvastatin therapy. Full trial inclusion criteria and details are deposited at clinicaltrials.org under the clinical trial identifier NCT01567826. Notably, 69 patients had previously been exposed to lower-intensity statin therapy, primarily atorvastatin (n = 29) and simvastatin (n = 23). At eight to ten weeks post-enrollment the patients underwent a staged PCI, the nonculprit lesion was re-imaged with OCT, and PBMC gene expression was again characterized by microarray. We ultimately obtained complete gene expression and OCT imaging data for 69 of these patients.
Microarray preparation and gene expression data
PBMCs were isolated from fasting blood samples by density gradient centrifugation using Ficollpaque, and mRNA was isolated using the TRIzol protocol. We used the Illumina HT-12 v4 microarray for gene expression profiling. We chose PBMCs because they are readily obtainable and gene expression signatures are robust across tissues [22] . All data preparation was conducted in R version 3.3.3 [23] . Quality control and normalization was accomplished with the lumi Bioconductor package [24, 25] with a variance-stabilizing transformation applied to background-adjusted probe intensities [26] . Normalization was performed with the quantile method. We corrected for batch effects resulting from staged microarray preparation using the ComBat parametric empirical Bayes technique in the R package sva [27] . Probe-togene mapping was conducted with the nuID mapping scheme implemented in lumi. The gene expression values are deposited in the NIH Gene Expression Omnibus (GEO) database with ID GSE86216.
FCT imaging by OCT
OCT images were obtained with the C7-XR OCT device (St. Jude Medical, Minneapolis, Minnesota) with continuous intracoronary contrast injection. The OCT catheter was placed at least 10 mm distal to
Research in context
Evidence before this study Acute myocardial infarction ("heart attack") results from the rupture of atherosclerotic plaques in the coronary arteries, with subsequent aggregation of platelets and formation of a clot that blocks the flow of blood through the artery, ultimately leading to tissue death in the heart. One of the key determinants of plaque rupture in the coronary arteries is the thickness of the fibrous cap that forms on top of plaque. When fibrous cap thickness (FCT) is larger, the plaque is more stable and less likely to rupture, and thus less likely to cause myocardial infarction. Drugs such as the statins function to increase FCT and thus reduce the risk of cardiovascular events. However, it is known that statins only increase fibrous cap thickness in a subset of patients. Not every patient prescribed a statin will have a beneficial increase in FCT. Unfortunately, accurate measurement of FCT is difficult in living patients. The best method to measure FCT is called optical coherence tomography, which requires threading an imaging wire into the coronary arteries to directly image the atherosclerotic plaque. Thus, it would be beneficial if a test could be performed that would be able to predict whether a patient's FCT will respond to statins without performing this invasive procedure.
Added value of this study
In this study, we demonstrate that gene expression data from patient's peripheral blood mononuclear cells can be used with high accuracy to demonstrate whether patients' fibrous caps will thicken in response to statin therapy. We do this by using two machine learning algorithms on the gene expression data, comparing their findings to findings obtained through invasive OCT imaging studies done on the same patients. We also demonstrate that clinical variables alone are not sufficient for predicting FCT response, nor do they add further utility to the gene expression based predictive models.
Implications of all the available evidence
This study demonstrates that change in FCT status in response to high-intensity rosuvastatin therapy can be predicted with very high fidelity in our sample of patients. After further study and validation, models such as ours may allow patients to have their FCT response approximated without undergoing invasive imaging. Before this test could be used in the clinic, it would need to successfully be shown of benefit through randomized, controlled clinical trials and the gene expression panel would need to be commercialized for clinical use. the target lesion, after which each OCT pullback imaged 54 mm of the vessel. OCT images were evaluated offline by an independent core laboratory (Cardiovascular Research Foundation, New York, New York) and analyzed at 1-mm intervals according to previously validated criteria for plaques characterization with the St. Jude Medical review workstation. The FCT of each lipid-rich plaque was measured three times at each time point at its thinnest point (6 measurements in total). The average value was then calculated for both baseline and follow-up time points for each patient (mean baseline and follow FCT). Finally, we calculated the change in FCT between baseline and follow-up timepoints by taking the absolute value of the difference. Compared to baseline, the location of the thinnest portion of the fibrous cap at follow-up remained the same in 65 of 69 patients (94.2%).
Responder identification
Each patient was identified as either a statin responder or nonresponder depending upon whether FCT increased or did not increase from baseline time point to follow-up time point (Fig. 1b) . We dichotomized this measurement because it is clinically meaningful to ascertain whether a patient's FCT will change in response to statin therapy, and thus whether statin therapy benefits a given patient. For example, in 2014, Kim et al. published a machine learning model using the expression levels of 100 genes to predict how LDL cholesterol levels in lymphoblastic cell lines changes following statin therapy [21] . This model for LDL cholesterol was able to classify the highest 15% of responders from the lowest 15% of responders with area under the ROC curve (AUC) up to 0.98 [28] . However, the model's utility diminished as they attempted to differentiate more moderate responders from moderate non-responders, with an AUC only modestly better than a random classifier (AUC b 0.6) for fully dichotomized data. Thus, for this initial step we chose to predict the binary outcome of response to statin therapy with increased FCT or not, instead of attempting to model the quantitative increase in cap thickness.
Statistical analysis
We used the glmnet [29] package in R [23] version 3.3.3 to fit elastic net regularized generalized linear models using a logistic link function via penalized maximum likelihood to transcriptomic data. The elastic net mixes the regression penalty of ridge regression with that of the least absolute shrinkage and selection operator (LASSO) regression. Elastic net coefficient estimates are computed by minimizing Eq. (1). Logistic regression in glmnet specifically solves the problem given in Eq. (2) for a sequence of λ values at a given α value. We search the mixing parameter α sequence in steps of 0.01 from α = 0 (full ridge regression) to α = 1 (full LASSO regression) for the value which minimizes the binomial deviance of the model, computed via leave-oneout cross validation (LOOCV) (Supplemental Material).
To fit K top scoring pair (KTSP) classifiers, we used the switchbox [30] Bioconductor R package. KTSP is an extension of the original Top Scoring Pairs (TSP) classification algorithm [31] . Briefly, given a matrix of expression values X with dimension genes x samples where columns 1 to N 1 are samples belonging to outcome class 1 and columns N 1+1 to N 2 are samples of class 2, KTSP finds the best pair of genes i and j which maximize the value Δ ij, as given in Eq. (3).
where P ij (1) and P ij (2) are given by Eqs. (4) and (5):
For the extension to K pairs of genes, the next highest top-scoring pairs of genes are added to the classifier for a given range of K. The addition of genes is penalized by choosing the value of K which produces a classifier that maximizes τ = δ i /σ i , where δ i is sum of K pairwise gene scores as given in Eq. (3) and σ i is the maximum-likelihood estimator of the variance [32] .
Incorporation of clinical variables into predictive models
To assess whether inclusion of clinical variables may help to alter or improve predictive performance, we conducted two additional analyses. First, we built an elastic net regression model as described above composed of only clinical variables. Second, we built another elastic net regression model as described above including both clinical variables as well as the transcriptomic data from the original elastic net model. A full list of clinical variables is included in the Supplemental Material.
Gene function analysis
We sought to ascertain the biological function of genes found to be predictive of FCT response by characterizing their Gene Ontology Enrichments. We used the TopGO R package to perform weighted Fisher Exact tests. We used the TopGO "weight01" algorithm to account for the hierarchical nature of Gene Ontology functional group assignments and to protect against false discovery from multiple hypothesis testing.
Results
FCT responder prediction
Clinical values for our patient cohort are available in Table 1 . The mean increase in FCT for rosuvastatin-responders was 36.9 ± 69.8 μm.
The mean change in FCT for rosuvastatin non-responders was −4.41 ± 7.05 μm. A plot demonstrating the distribution of FCT values is available in the Supplementary Material. LDL cholesterol and total cholesterol levels were not significantly different between responder and non-responders, either at baseline, follow-up, or when examining change in lipid levels from baseline to follow-up (Supplementary Material, Table S3 ). Using transcriptomic data to predict FCT response, we obtained a final model with leave-one-out-cross-validation (LOOCV) area under the receiver operating characteristic curve of 0.975. We thus could classify individuals as FCT statin responders or non-responders with high fidelity. The elastic net model using 73 genes had an accuracy of 92.8%, sensitivity of 94.1%, and specificity of 91.4%. Similarly, the KTSP classifier could discriminate between responders and non-responders with high performance, obtaining LOOCV accuracy of 95.7%, sensitivity of 94.3%, and specificity of 97.1% (Fig. 2a) . Notably, this classifier required only 18 genes. Fig. 3 provides a visual demonstration of how well this small number of genes divide responders and non-responders. 
Sensitivity testing
When constructing predictive models, the potential for overfitting the training dataset is of high concern, especially when sample sizes are small. We conducted extensive cross validation and sensitivity testing to characterize the stability of our predictive models to patient sampling (Fig. 1d) . Briefly, our strategy for sensitivity testing was to (1) randomly split the data in half; (2) build a predictive model on half of the data, using LOOCV to select the most robust model; (3) test this model on the remaining held out 50% of data to obtain a true testset validation of the model. We then repeated steps 1-3 1000 times to gain insight into the sensitivity of this model-building procedure and distributions of the model statistics (Fig. 2b and c) .
We could predict FCT responder status in a held-out test set with high discrimination. The median elastic net AUC was 0.969, and the median KTSP AUC was 0.972. Our sensitivity analysis revealed that even the lower-performing models still performed with high accuracy on the held-out testing set: 97% of the elastic net models has AUCs of better than 0.886, and 97% of the KTSP models had AUCs better than 0.946.
Incorporation of clinical variables into predictive models
After discovering that the transcriptome-only model provided excellent results for predictive models, we explored whether clinical variables could either augment or replace our transcriptome-based predictive models. We included 49 different clinical and laboratory parameters. A full table of clinical variables is given in the supplementary material Table S2 . We followed identical training procedures to those described above for the transcriptome-only model. An elastic net trained on transcriptome plus clinical data produced identical results to the elastic net trained on transcriptome data alone. The elastic net training algorithm did not select any clinical variables for inclusion in the final predictive model, instead choosing the same 73 genes. An elastic net trained on the clinical variables only and then used to predict FCT response performed very poorly (AUC = 0.16, Accuracy = 0.33, Sensitivity = 0.09, Specificity = 0.57) (Supplementary Fig. 3 ). In fact, the very poor AUC of this model mean that is performed well below random chance (AU = 0.5). Theoretically, simply flipping each of this model's predictions would have made it perform moderately well (AUC 0.83). However, it would be statistically unfair to reverse model predictions after looking at the outcome of the trained model on the test set.
Gene ontology term enrichment
Our elastic net regression model utilized 73 gene expression values ( Table 2) . The final KTSP model used only 18 genes (nine pairs of topscoring genes) ( Table 3 ). 12 of the 18 genes from the KTSP algorithm were present in the elastic net regression selected genes (Fig. 4) . We performed Gene Ontology (GO) biological process enrichment testing upon significant elastic net covariates to understand biological processes which may regulate the fibrous cap thickening response to statin therapy. GO terms are a controlled vocabulary of curated genes and gene products mapped to specific biological processes, molecular functions, and cellular components. We found 58 significant GO term enrichments at p b .05, including many involved with (1) immune cell function (GO terms: locomotion involved in locomotory behavior; T cell homeostasis; positive regulation of MHC class I biosynthesis; positive regulation of NK T cell activation; negative regulation of T cell mediated cytotoxicity; monocyte activation), and (2) cholesterol metabolism (cholesterol catabolic process; cholesterol import; C21-steroid hormone metabolic process; SREBP signaling pathway), and (3) protein modification (protein phosphorylation; protein adenylylation; protein K11-linked ubiquitination; N-terminal peptidyl-lysine acetylation; protein K48-linked ubiquitination). A full table of GO terms with associated p values is available in the Supplementary Material, Table S4 .
Discussion
In this post-hoc analysis of the Yellow-II study, we demonstrate that gene expression (when characterized via microarray with statistical models capable of dealing with high-dimensional gene expression data) can be used to reliably predict whether a given patient's fibrous cap thickness will increase with statin treatment. Our study is one of the first attempts to use predictive modeling techniques applied to transcriptomic data to predict plaque response to lipid lowering therapy. Transcriptomic profiling has been used for many years in cardiovascular research to identify genes differentially expressed between cases and controls in a variety of diseases [33] , or somewhat more recently to analyze putative biological interactions using methods such as weighted gene coexpression networks [34, 35] . We attempted to, instead of simply identifying statistically differentially expressed genes across a condition, use gene expression data to predict outcomes. In fact, statistically significant variables (e.g., differentially expressed genes) are often poorly predictive variables [36] , and often explain only a fraction of the variance in the outcome. To accurately predict an outcome, one must instead explain a significant fraction of the outcome variance, which is a more difficult task. In the present study, we explain much of the variance in outcome as demonstrated by our high prediction statistics (AUCs on the order of 0.95). For clinically applicable personalized medicine, a physician would be interested in a test which is predictive of an outcome for an individual patient, such as the test we present here.
Second, we demonstrate that the genes which are most predictive of FCT response to statin therapy are those broadly involved in immune cell function, cholesterol biosynthesis and metabolism, and cellular protein modification processes such as phosphorylation and adenylation. A number of researchers have linked fibrous cap production and degradation to inflammatory processes [37] . The same statin used in the Yellow II trial-rosuvastatin-was demonstrated to reduce major cardiovascular events in the JUPITER study with elevated levels of the nonspecific inflammatory marker c-reactive protein (CRP) [38] but presumably normal cholesterol levels. Indeed, we have previously demonstrated in this cohort an inverse relationship between CRP levels and FCT [6, 39] . Through MRI-PET/CT and mathematical fluid-structure-interaction modeling it was observed that in mice that cap inflammation can lead to increased cap strain, especially in the presence of thin-caps and hypertension [40] . The CANTOS trial of the Interleukin-1β (IL-1β) monoclonal antibody successfully demonstrated that selective anti- inflammatory therapy can reduce the incidence of adverse cardiovascular events [41] . Other recent work has focused upon the role of IL-1β-modulated neutrophils in the atherosclerotic plaque [42] , or the roles of neutrophil extracellular traps [43, 44] . Another recent paper has demonstrated that neutrophil reprogramming can modulate chronic inflammation in atherosclerosis [45] . We note that two important proteins related to neutrophil extravasation, XCR1 and XRCC5, were important in our elastic net predictive model. On the other hand, at least one recent paper has experimentally demonstrated in mice the unexpected finding that IL-1β may actually reduce protective remodeling of atherosclerotic fibrous caps [46] . Whatever the ultimate effect of this particular inflammatory mediator, it is evident that inflammatory processes play an important role in the development of atherosclerosis, and it is thus not surprising that these genes also can be used for prediction of FCT response. Similarly, OCT imaging and intravascular ultrasound imaging have demonstrated that synthesis and absorption of cholesterol were related to plaque vulnerability and FCT, and also that HDL-C was an independent marker for FCT; these findings echo previous results of the YELLOW-II study [6, [47] [48] [49] [50] . A number of other genes used by both the elastic net and KTSP algorithms may be of interest for further investigation of their role in the formation of atherosclerotic fibrous caps. For example, TAOK1 is a ubiquitously expressed kinase with important identified roles in modulation of interleukin-17 [51] . Interestingly, TAOK1 has been shown in vascular smooth muscle to be differentially expressed following the administration of captopril and is also involved in the angiotensin-II-mediated mitogen-activated protein kinsase signaling pathway [52] . The gene ZRANB2 has shown to regulate the process of vasculogenic mimicry in neoplams [53] and also to be involved in the immunologic response to gram-negative bacteria [54] . The intracellular calcium-binding protein calbindin 2 (CALB2) plays a role in a number of cellular functions, such as the buffering of intracellular calcium, and has been implicated in vascular smooth muscle cell adhesion [55] , cardiogenic differentiation [56] , cellular response to ischemia [57] , steroidogenesis [58] . Finally, we were interested in the negative correlation between expression of steroidogenic acute regulator-related lipid transfer domain protein (STARD5) and FCT response. This family of proteins, which modulate intracellular lipid and cholesterol transport, have been investigated for their roles in cholesterol and lipid metabolism [59, 60] as well as their function in atherogenic lipid phenotypes [61] and fibroblast function [62] . This gene also has been identified as an emerging cardiovascular disease risk biomarker [63] . 
Study limitations
Our study must be interpreted in the light of its limitations. The major limitation to this study is the limited sample size, essentially due to the invasive nature of repeated OCT imaging. We are exploring options for external validation, which would require a second clinical trial. However, we are comforted by the extensive cross validation efforts we undertook to test that we are not overfitting our model to the dataset. Furthermore, the gene expression results have been previously validated in the Yellow II study [6] . Second, there are currently few transcriptome-based tests utilized in cardiovascular medicine, and likely none used in routine clinical cardiology. In this measure, cardiovascular disease has lagged behind other fields such as oncology, which have rapidly embraced transcriptome characterization via microarray and RNA sequencing [64] . However, there is no fundamental reason that transcriptomic medicine will not ultimately prove to be useful in cardiovascular medicine, especially as future efforts toward precision cardiology increase [65] [66] [67] . However, we caution that this pilot study requires validation in a randomized, controlled clinical trial before its results could be applied clinically.
Conclusions
Taken altogether, we believe our results represent a step toward enabling statin therapy recommendation based upon the patient's transcriptome in chronic cardiovascular disease. OCT is a precise and highly useful technique with a large body of existing literature, and it would require further validation studies before a transcriptomic approach could be used with confidence in the clinic. However, our findings here are promising: a non-invasive, blood-based test appears to detect with high sensitivity and specificity whether an individual patient in our sample will benefit from high intensity statin therapy. Since FCT is associated with systemic cardiovascular disease outcomes and risk of myocardial infarction, development of a non-invasive diagnostic test for patient response is potentially of high clinical interest. We envision that predicted non-responders to statin therapy may benefit from additional intervention, such as earlier introduction of PCSK9 inhibitors.
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